company background image
A207940 logo

Samsung BiologicsLtd KOSE:A207940 Stock Report

Last Price

₩1.05m

Market Cap

₩74.4t

7D

-2.2%

1Y

32.3%

Updated

12 Apr, 2025

Data

Company Financials +

Samsung Biologics Co.,Ltd.

KOSE:A207940 Stock Report

Market Cap: ₩74.4t

A207940 Stock Overview

Together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. More details

A207940 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Samsung Biologics Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Samsung BiologicsLtd
Historical stock prices
Current Share Price₩1,045,000.00
52 Week High₩1,209,000.00
52 Week Low₩721,000.00
Beta0.43
1 Month Change-0.76%
3 Month Change4.50%
1 Year Change32.28%
3 Year Change25.15%
5 Year Change84.63%
Change since IPO625.69%

Recent News & Updates

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

Apr 11
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

Samsung Biologics Co.,Ltd.'s (KRX:207940) Popularity With Investors Is Under Threat From Overpricing

Feb 25
Samsung Biologics Co.,Ltd.'s (KRX:207940) Popularity With Investors Is Under Threat From Overpricing

Recent updates

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

Apr 11
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

Samsung Biologics Co.,Ltd.'s (KRX:207940) Popularity With Investors Is Under Threat From Overpricing

Feb 25
Samsung Biologics Co.,Ltd.'s (KRX:207940) Popularity With Investors Is Under Threat From Overpricing

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Dec 24
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected

Nov 11
Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected

These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well

Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up

Jul 29
Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up

Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

May 27
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?

What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Apr 14
What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You

Shareholder Returns

A207940KR Life SciencesKR Market
7D-2.2%-0.08%-1.0%
1Y32.3%37.1%-11.5%

Return vs Industry: A207940 underperformed the KR Life Sciences industry which returned 37.1% over the past year.

Return vs Market: A207940 exceeded the KR Market which returned -11.5% over the past year.

Price Volatility

Is A207940's price volatile compared to industry and market?
A207940 volatility
A207940 Average Weekly Movement5.2%
Life Sciences Industry Average Movement5.3%
Market Average Movement6.1%
10% most volatile stocks in KR Market12.5%
10% least volatile stocks in KR Market2.8%

Stable Share Price: A207940 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A207940's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20114,770John Chongbo Rimsamsungbiologics.com

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing.

Samsung Biologics Co.,Ltd. Fundamentals Summary

How do Samsung BiologicsLtd's earnings and revenue compare to its market cap?
A207940 fundamental statistics
Market cap₩74.38t
Earnings (TTM)₩1.08t
Revenue (TTM)₩4.55t

68.7x

P/E Ratio

16.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A207940 income statement (TTM)
Revenue₩4.55t
Cost of Revenue₩2.27t
Gross Profit₩2.27t
Other Expenses₩1.19t
Earnings₩1.08t

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 23, 2025

Earnings per share (EPS)15.22k
Gross Margin50.01%
Net Profit Margin23.82%
Debt/Equity Ratio12.3%

How did A207940 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/12 16:25
End of Day Share Price 2025/04/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Samsung Biologics Co.,Ltd. is covered by 46 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Hyeryeong KimCGS International
Jun LimCGS International